课题基金 / 基金详情

项目摘要

项目成果

NICHOLAS J DYSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project summary For simplicity we tend to imagine that most proteins have a single mechanism of action. The retinoblastoma tumor suppressor is an example of a protein that defies this simple classification. RB1 is functionally inactivated in most human cancers and the molecular properties of its protein product (RB) have been studied intensively. Despite this research, RB's mechanism of action has remained an enigma. RB has been reported to physically associate with hundreds of proteins and many different interactions have been proposed to contribute to its tumor suppressive properties. The RB research community is faced with a conundrum: which of these interactions are real, which are not, and how could one protein co-ordinate its effects on so many potential targets? Recent studies from several laboratories have suggested that the answers to these questions lie in a code of RB phosphorylation. The concept is that normal cells do not contain a single form of RB, but that differential phosphorylation generates multiple isoforms of RB that have different binding properties and, presumably, perform different roles. In essence, the action of RB is tailored by phosphorylation. RB is known to have 14 sites of CDK phosphorylation. We have recently developed methods that allow us to use mass spectrometry-based proteomics to profile RB complexes. We have also generated panels of isogenic cell cultures in which we can replace the endogenous RB protein with mutant RB proteins that contain just a single cdk phosphorylation site, or a single phospho-mimicking mutation. In this application we propose to use these tools to decipher this code of RB phosphorylation. In Aim 1 we will use state-of-the-art proteomics to define the binding properties of each of the mono-phosphorylated isoforms of RB. In Aim 2 we will identify the functional consequences of these interactions by identifying the transcriptional programs that they control and by genomic loci that they target. Using this binding information and transcription profiles we will identify the molecular interactions that allow specific mono-phosphorylated isoforms of RB to control distinct programs of transcription. Together these experiments will generate a framework of molecular information that is critical to be able to understand RB's mechanism of action.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.xpro.2022.101991
发表时间: 2023-03-17
期刊: STAR PROTOCOLS
影响因子: --
作者: [Lee, Hanjun, Sanidas, Ioannis, Dyson, Nicholas J., Lawrence, Michael S.]
通讯作者: Lawrence, Michael S.
DOI: 10.1080/15384101.2023.2206352
发表时间: 2023-06
期刊: CELL CYCLE
影响因子: 4.3
作者: [Krishnan, Badri, Sanidas, Ioannis, Dyson, Nicholas J.]
通讯作者: Dyson, Nicholas J.
DOI: 10.1083/jcb.202102144
发表时间: 2022-03-07
期刊: The Journal of cell biology
影响因子: --
作者: [Krishnan B, Yasuhara T, Rumde P, Stanzione M, Lu C, Lee H, Lawrence MS, Zou L, Nieman LT, Sanidas I, Dyson NJ]
通讯作者: Dyson NJ
DOI: 10.1016/j.molcel.2022.07.014
发表时间: 2022-09-15
期刊: MOLECULAR CELL
影响因子: 16
作者: [Sanidas, Ioannis, Lee, Hanjun, Rumde, Purva H., Boulay, Gaylor, Morris, Robert, Golczer, Gabriel, Boulay, Hanjun Gaylor, Stanzione, Marcelo, Hajizadeh, Soroush, Zhong, Jun, Ryan, Meagan B., Corcoran, Ryan B., Drapkin, Benjamin J., Rivera, Miguel N., Dyson, Nicholas J., Lawrence, Michael S.]
通讯作者: Lawrence, Michael S.
Using patient-derived models to understand drug responses in SCLC
  • 批准号:
    10456908
  • 项目类别:
  • 资助金额:
    $59.91万
  • 财政年份:
    2018
  • 负责人:
    NICHOLAS J DYSON
  • 依托单位:
Using patient-derived models to understand drug responses in SCLC
  • 批准号:
    10247067
  • 项目类别:
  • 资助金额:
    $61.34万
  • 财政年份:
    2018
  • 负责人:
    NICHOLAS J DYSON
  • 依托单位:
Deciphering the code of RB phosphorylation
  • 批准号:
    10187530
  • 项目类别:
  • 资助金额:
    $50.32万
  • 财政年份:
    2018
  • 负责人:
    NICHOLAS J DYSON
  • 依托单位:
Dissection and manipulation of RB function
  • 批准号:
    9107393
  • 项目类别:
  • 资助金额:
    $36.11万
  • 财政年份:
    2012
  • 负责人:
    NICHOLAS J DYSON
  • 依托单位:
海外基金